Can a rapid test diagnose sickle cell at the bedside?

Sickle SCAN, a point-of-care immunoassay, was validated against laboratory gold standards for detecting hemoglobin S and related genotypes.

Keep what you just learned

Save these 11 cards to your NoteFren library. Your first review starts right away, and each card links back to the study it came from.

What device was validated?

Sickle SCAN, a novel point-of-care testing device for sickle cell disease.

Against what standards was accuracy judged?

Hemoglobin electrophoresis or HPLC gold-standard diagnostics.

How many clinical samples were compared?

137 patient samples, each measured in duplicate on Sickle SCAN.

What LoDs were reported for HbA, HbS, and HbC?

40% for HbA, 1% for HbS, and 2% for HbC.

Why keep HbA LoD relatively high?

To diagnose HbSβ+ as HbS while distinguishing HbAS with >40% HbA, and to keep HbS/HbC LoDs useful in neonates.

Did common interferents break the assay?

No interference at the tested concentrations of protein, penicillin, hydroxyurea, bilirubin, and cholesterol.

Which genotypes was the test meant to confirm?

Sickle trait (HbAS) and SCD genotypes including HbSS, HbSC, HbSβ0, and HbSβ+.

How do authors refer to electrophoresis/HPLC results?

Interchangeably as gold standard diagnostics.

What reading-time experiment did they perform?

They scanned AA and SC samples from 5 minutes through 24 hours to determine optimal interpretation time.

Why does rapid SCD diagnosis matter clinically?

Early diagnosis enables preventive care such as prophylactic antibiotics and family education about complications.

What study type label does the journal give this paper?

A technical advance focused on validating a novel point-of-care test.